A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months

This first in human study was designed as an open label clinical trial to assess the safety and immunogenicity of SIIPL DTwP-HepB-IPV-Hib (Hexavalent) combination vaccine in healthy toddlers, aged 16–24 months. A total of 24 healthy toddlers were administered a 0.5 ml single dose of SIIPL DTwP-HepB-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Hitt, Lalwani, Sanjay, Parekh, Sameer, Pujari, Pramod, Shewale, Sunil, Palkar, Sonali, Hanumante, Neeta, Gokhale, Shilpa, Ks, Jaganathan, Kumar, Rakesh, Sharma, Inderjit, Gairola, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Licensed Vaccines – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746440/
https://www.ncbi.nlm.nih.gov/pubmed/36412272
http://dx.doi.org/10.1080/21645515.2022.2146435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746440/
https://www.ncbi.nlm.nih.gov/pubmed/36412272
http://dx.doi.org/10.1080/21645515.2022.2146435

Ejemplares similares